艰难梭菌相关性腹泻复发或再感染的流行病学
Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea.
作者信息
Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit J C
机构信息
Department of Microbiology, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France.
出版信息
J Clin Microbiol. 2000 Jun;38(6):2386-8. doi: 10.1128/JCM.38.6.2386-2388.2000.
Abstract
Approximately 15 to 35% of patients with a first episode of Clostridium difficile-associated diarrhea relapse within 2 months. Between 1994 and 1997, strains from 93 hospitalized patients with C. difficile recurrences were fingerprinted by using both serotyping and PCR-ribotyping. The results showed that 48.4% of clinical recurrences were, in fact, reinfections with a different strain of C. difficile. Rates of clinical recurrences could therefore be reduced by implementing strict isolation precautions.
摘要
首次发作艰难梭菌相关性腹泻的患者中，约15%至35%会在2个月内复发。1994年至1997年期间，对93例艰难梭菌复发的住院患者的菌株进行了血清分型和PCR核糖体分型指纹图谱分析。结果显示，实际上48.4%的临床复发是由不同菌株的艰难梭菌再次感染所致。因此，通过实施严格的隔离预防措施可以降低临床复发率。
相似文献
1
Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea.艰难梭菌相关性腹泻复发或再感染的流行病学
J Clin Microbiol. 2000 Jun;38(6):2386-8. doi: 10.1128/JCM.38.6.2386-2388.2000.
2
Molecular epidemiology of Clostridium difficile strains in children compared with that of strains circulating in adults with Clostridium difficile-associated infection.比较儿童艰难梭菌菌株与成人艰难梭菌相关性感染中流行的菌株的分子流行病学。
J Clin Microbiol. 2011 Nov;49(11):3994-6. doi: 10.1128/JCM.05349-11. Epub 2011 Sep 21.
3
Epidemiology and molecular characterization of Clostridium difficile strains from patients with diarrhea: low disease incidence and evidence of limited cross-infection in a Swedish teaching hospital.腹泻患者艰难梭菌菌株的流行病学及分子特征：瑞典一家教学医院疾病发病率低且交叉感染有限的证据
J Clin Microbiol. 2003 Sep;41(9):4031-7. doi: 10.1128/JCM.41.9.4031-4037.2003.
4
Association of relapse of Clostridium difficile disease with BI/NAP1/027.艰难梭菌疾病复发与 BI/NAP1/027 的关联。
J Clin Microbiol. 2012 Dec;50(12):4078-82. doi: 10.1128/JCM.02291-12. Epub 2012 Oct 10.
5
Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent clostridium difficile-associated diarrhea.对从18例复发性艰难梭菌相关性腹泻病例中分离出的艰难梭菌菌株进行分子分析。
J Clin Microbiol. 2003 Jul;41(7):3413-4. doi: 10.1128/JCM.41.7.3413-3414.2003.
6
Clostridium difficile infection in outpatients, Maryland and Connecticut, USA, 2002-2007.2002-2007 年美国马里兰州和康涅狄格州的门诊艰难梭菌感染。
Emerg Infect Dis. 2011 Oct;17(10):1946-9. doi: 10.3201/eid1710.110069.
7
Molecular epidemiology of toxigenic Clostridioides difficile isolates from hospitalized patients and the hospital environment in Dhaka, Bangladesh.孟加拉国达卡住院患者和医院环境中产毒艰难梭菌分离株的分子流行病学研究。
Anaerobe. 2020 Feb;61:102081. doi: 10.1016/j.anaerobe.2019.102081. Epub 2019 Jul 26.
8
Prevalence and genetic characterization of toxin A variant strains of Clostridium difficile among adults and children with diarrhea in France.法国腹泻成人和儿童中艰难梭菌毒素A变异菌株的流行情况及基因特征
J Clin Microbiol. 2002 Jun;40(6):2079-83. doi: 10.1128/JCM.40.6.2079-2083.2002.
9
Molecular epidemiology of predominant and emerging Clostridioides difficile ribotypes.主要和新兴艰难梭菌核糖体分型的分子流行病学。
J Microbiol Methods. 2020 Aug;175:105974. doi: 10.1016/j.mimet.2020.105974. Epub 2020 Jun 10.
10
PCR amplification of rRNA intergenic spacer regions as a method for epidemiologic typing of Clostridium difficile.聚合酶链反应扩增rRNA基因间隔区作为艰难梭菌流行病学分型方法
J Clin Microbiol. 1995 Jan;33(1):184-7. doi: 10.1128/jcm.33.1.184-187.1995.
引用本文的文献
1
Fecal microbiota transplantation: present and future.粪便微生物群移植：现状与未来。
Clin Endosc. 2025 May;58(3):352-359. doi: 10.5946/ce.2024.270. Epub 2025 Mar 25.
2
Safety and Efficacy of Fecal Microbiota, Live-jslm, in Preventing Recurrent Infection in Participants Who Were Mildly to Moderately Immunocompromised in the Phase 3 PUNCH CD3-OLS Study.在3期PUNCH CD3-OLS研究中，粪菌微生物群Live-jslm预防轻度至中度免疫功能低下参与者复发性感染的安全性和有效性。
Open Forum Infect Dis. 2025 Mar 4;12(4):ofaf117. doi: 10.1093/ofid/ofaf117. eCollection 2025 Apr.
3
Cell Wall Protein 2 as a Vaccine Candidate Protects Mice Against Infection.细胞壁蛋白2作为候选疫苗可保护小鼠免受感染。
Vaccines (Basel). 2024 Dec 30;13(1):21. doi: 10.3390/vaccines13010021.
4
Characterization of heparin interactions with Clostridioides difficile toxins and its potential as anti-CDI therapeutics.肝素与艰难梭菌毒素的相互作用及其作为抗艰难梭菌感染治疗药物的潜力的表征。
Carbohydr Polym. 2025 Mar 1;351:123143. doi: 10.1016/j.carbpol.2024.123143. Epub 2024 Dec 12.
5
Clostridioides difficile Biofilm.艰难梭菌生物膜。
Adv Exp Med Biol. 2024;1435:249-272. doi: 10.1007/978-3-031-42108-2_12.
6
Predictive value of fecal calprotectin and lactoferrin levels for negative outcomes in Clostridioides difficile infection.粪便钙卫蛋白和乳铁蛋白水平对艰难梭菌感染阴性结局的预测价值。
Eur J Clin Microbiol Infect Dis. 2024 Feb;43(2):313-324. doi: 10.1007/s10096-023-04729-z. Epub 2023 Dec 11.
7
Microbiome profile and calprotectin levels as markers of risk of recurrent infection.微生物组特征和钙卫蛋白水平作为复发性感染风险的标志物。
Front Cell Infect Microbiol. 2023 Sep 13;13:1237500. doi: 10.3389/fcimb.2023.1237500. eCollection 2023.
8
The cell wall lipoprotein CD1687 acts as a DNA binding protein during deoxycholate-induced biofilm formation in Clostridioides difficile.艰难梭菌在脱氧胆酸钠诱导生物膜形成过程中，细胞壁脂蛋白 CD1687 作为一种 DNA 结合蛋白发挥作用。
NPJ Biofilms Microbiomes. 2023 May 11;9(1):24. doi: 10.1038/s41522-023-00393-5.
9
Adoption and Trends in Uptake of Updated ICD-10 Codes for -A Retrospective Observational Study.采用更新的ICD - 10编码的情况及使用趋势——一项回顾性观察研究
Open Forum Infect Dis. 2022 Nov 14;9(12):ofac622. doi: 10.1093/ofid/ofac622. eCollection 2022 Dec.
10
The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model.艰难梭菌感染模型中粪便微生物移植与万古霉素的疗效评价。
Appl Microbiol Biotechnol. 2022 Oct;106(19-20):6689-6700. doi: 10.1007/s00253-022-12154-z. Epub 2022 Sep 10.
本文引用的文献
1
Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing.基于核糖体RNA基因测序开发一种用于艰难梭菌的新型PCR核糖体分型方法。
FEMS Microbiol Lett. 1999 Jun 15;175(2):261-6. doi: 10.1111/j.1574-6968.1999.tb13629.x.
2
Review article: treatment of Clostridium difficile infection.综述文章：艰难梭菌感染的治疗
Aliment Pharmacol Ther. 1997 Dec;11(6):1003-12. doi: 10.1046/j.1365-2036.1997.00269.x.
3
Infection control and prevention of Clostridium difficile infection.艰难梭菌感染的感染控制与预防
J Antimicrob Chemother. 1998 May;41 Suppl C:59-66. doi: 10.1093/jac/41.suppl_3.59.
4
The epidemiology and typing of Clostridium difficile.艰难梭菌的流行病学与分型
J Antimicrob Chemother. 1998 May;41 Suppl C:47-57. doi: 10.1093/jac/41.suppl_3.47.
5
Treatment of Clostridium difficile infection.艰难梭菌感染的治疗
J Antimicrob Chemother. 1998 May;41 Suppl C:41-6. doi: 10.1093/jac/41.suppl_3.41.
6
Clinical impact and associated costs of Clostridium difficile-associated disease.艰难梭菌相关性疾病的临床影响及相关成本
J Antimicrob Chemother. 1998 May;41 Suppl C:5-12. doi: 10.1093/jac/41.suppl_3.5.
7
Recurrence of symptoms in Clostridium difficile infection--relapse or reinfection?艰难梭菌感染中症状的复发——复发还是再感染？
J Hosp Infect. 1998 Feb;38(2):93-100. doi: 10.1016/s0195-6701(98)90062-7.
8
9
Comparison of PCR-based approaches to molecular epidemiologic analysis of Clostridium difficile.基于聚合酶链反应的艰难梭菌分子流行病学分析方法比较
J Clin Microbiol. 1996 May;34(5):1153-7. doi: 10.1128/jcm.34.5.1153-1157.1996.
10
Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study.住院患者艰难梭菌的患病率及致病性。一项法国多中心研究。
Arch Intern Med. 1996 Jul 8;156(13):1449-54.
Zotero 插件